Macular Edema News

Report Explores the Macular Edema Market Latest Trends and Insights by 2025 - MilTech



Report Explores the Macular Edema Market Latest Trends and Insights by 2025 
MilTech
Macula is the oval yellowish area surrounding the focal point of the retina in the eye. Macular edema is the state when liquid and protein begin collecting under the macula leading to swelling in the eye. Focal vision of the eye gets mutilated because ...

and more » 


High-dose intravitreal triamcinolone acetonide treats macular edema for up to 6 months - Healio



High-dose intravitreal triamcinolone acetonide treats macular edema for up to 6 months 
Healio
One injection of decanted high-dose intravitreal triamcinolone acetonide can provide a 6-month treatment for patients with treatment-resistant persistent macular edema, according to a study. Researchers examined the effects of decanted high-dose ...

 


Global Macular Edema Market and Competitive Landscape - 2017 - Research and Markets - Business Wire (press release)



Global Macular Edema Market and Competitive Landscape - 2017 - Research and Markets 
Business Wire (press release)
The latest research, Global Macular Edema Market and Competitive Landscape - 2017, provides comprehensive insights into Macular Edema pipeline, epidemiology, market valuations, product sales, market forecast, product forecasts, and market shares.

and more » 


Early Treatment of Diabetic Retinopathy and Diabetic Macular Edema - Healio



Early Treatment of Diabetic Retinopathy and Diabetic Macular Edema 
Healio
Diabetic retinopathy (DR) and diabetic macular edema (DME) are 2 of the most common causes of blindness among working-age people throughout the world. Effective management depends heavily on prompt treatment. Many of these patients remain ...

 


CRT, Vision Loss Have Complex Relationship - MD Magazine



MD Magazine
 
CRT, Vision Loss Have Complex Relationship 
MD Magazine
... coherence tomography (SD-OCT) exist to some degree in age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO), the relationships show a wide variance and may be complicated by other disease factors.

 


AntriaBio Announces Selection of Lead Oral Plasma Kallikrein Inhibitor Candidates for the Treatment of Diabetic ... - GlobeNewswire (press release)



AntriaBio Announces Selection of Lead Oral Plasma Kallikrein Inhibitor Candidates for the Treatment of Diabetic ... 
GlobeNewswire (press release)
LOUISVILLE, Colo., Oct. 17, 2017 (GLOBE NEWSWIRE) -- AntriaBio, Inc. (?AntriaBio? or the ?Company?) (OTCQB:ANTB), a biopharmaceutical company focused on developing therapies to address significant unmet medical needs, today announced that it is ...

and more » 


Clearside Biomedical, Inc. (NASDAQ:CLSD) Trading Volume Significantly Lower - HugoPress



Clearside Biomedical, Inc. (NASDAQ:CLSD) Trading Volume Significantly Lower 
HugoPress
Its products include CLS-1001 for the treatment of macular edema associated with non-infectious uveitis; CLS-1003 for the treatment of macular edema associated with retinal vein occlusion; and CLS-1002 program for the treatment of wet age-related ...

and more » 


Noninvasive, High-Resolution Functional Macular Imaging in Subjects With Retinal Vein Occlusion - Healio



Healio
 
Noninvasive, High-Resolution Functional Macular Imaging in Subjects With Retinal Vein Occlusion 
Healio
Also, study Patient 7 had a total of four arterioles segmented; the lower number of segments available for analysis for this subject was the result of severe edema and intraretinal hemorrhage in the macular region leading to poor optical resolution ...

 


Kalvista Pharmaceuticals Inc (NASDAQ:KALV) To Collaborate With Merck & Co., Inc. (NYSE:MRK) On A Diabetic ... - Market Exclusive



Market Exclusive
 
Kalvista Pharmaceuticals Inc (NASDAQ:KALV) To Collaborate With Merck & Co., Inc. (NYSE:MRK) On A Diabetic ... 
Market Exclusive
Pharmaceutical giant Merck & Co., Inc. (NYSE:MRK) is paying approximately $37 million for an upfront option to acquire a program Kalvista Pharmaceuticals Inc (NASDAQ:KALV) has for the treatment of DME ? diabetic macular edema. This is a condition ...
KalVista Pharmaceuticals, Inc. (KALV) Director Rajeev M. Shah Purchases 850000 Shares Dispatch Tribunal
Breaking: KalVista Pharmaceuticals (KALV) ?Buy? Rating Reiterated at BTIG Research Today; The TP is $27 BZ Weekly

all 76 news articles » 


Aflibercept helps in ME patients with DR after cataract surgery - ModernMedicine



Aflibercept helps in ME patients with DR after cataract surgery 
ModernMedicine
Take-home: Patients with diabetic retinopathy have a high risk of developing macular edema after cataract surgery. Intravitreal injections of aflibercept might result in fewer patients developing macular edema in this patient population. The PROMISE ...